Keith S. Ehrlich
Nessuna posizione attualmente
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| Tuan Ha-Ngoc | M | 72 | 13 anni | |
| Safi R. Bahcall | M | 55 |
Synta Pharmaceuticals Corp.
 Synta Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Synta Pharmaceuticals Corp. discovers, develops and commercializes pharmaceutical products. It focuses on the research, development and commercialization of oncology medicines that provides treatment to cancer patients. The company is also developing a proprietary platform for delivery of anti-cancer drugs directly to tumor cells, known as Hsp90-inhibitor drug conjugates. Synta Pharmaceuticals was founded by Safi R. Bahcall and Lan-Bo Chen in March 2000 and is headquartered in Lexington, MA. | 14 anni |
| Chen Schor | M | 51 |
Synta Pharmaceuticals Corp.
Synta Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Synta Pharmaceuticals Corp. discovers, develops and commercializes pharmaceutical products. It focuses on the research, development and commercialization of oncology medicines that provides treatment to cancer patients. The company is also developing a proprietary platform for delivery of anti-cancer drugs directly to tumor cells, known as Hsp90-inhibitor drug conjugates. Synta Pharmaceuticals was founded by Safi R. Bahcall and Lan-Bo Chen in March 2000 and is headquartered in Lexington, MA. | 2 anni |
| David J. McLachlan | M | 86 | 17 anni | |
| Anne Michelle Whitaker | F | 56 |
Synta Pharmaceuticals Corp.
Synta Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Synta Pharmaceuticals Corp. discovers, develops and commercializes pharmaceutical products. It focuses on the research, development and commercialization of oncology medicines that provides treatment to cancer patients. The company is also developing a proprietary platform for delivery of anti-cancer drugs directly to tumor cells, known as Hsp90-inhibitor drug conjugates. Synta Pharmaceuticals was founded by Safi R. Bahcall and Lan-Bo Chen in March 2000 and is headquartered in Lexington, MA. | 1 anni |
| Henri A. Termeer | M | 78 | 6 anni | |
| George Farmer | M | - |
Synta Pharmaceuticals Corp.
Synta Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Synta Pharmaceuticals Corp. discovers, develops and commercializes pharmaceutical products. It focuses on the research, development and commercialization of oncology medicines that provides treatment to cancer patients. The company is also developing a proprietary platform for delivery of anti-cancer drugs directly to tumor cells, known as Hsp90-inhibitor drug conjugates. Synta Pharmaceuticals was founded by Safi R. Bahcall and Lan-Bo Chen in March 2000 and is headquartered in Lexington, MA. | - |
| Steven B. Bernitz | M | 78 |
Synta Pharmaceuticals Corp.
Synta Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Synta Pharmaceuticals Corp. discovers, develops and commercializes pharmaceutical products. It focuses on the research, development and commercialization of oncology medicines that provides treatment to cancer patients. The company is also developing a proprietary platform for delivery of anti-cancer drugs directly to tumor cells, known as Hsp90-inhibitor drug conjugates. Synta Pharmaceuticals was founded by Safi R. Bahcall and Lan-Bo Chen in March 2000 and is headquartered in Lexington, MA. | 1 anni |
| Marc R. Schneebaum | M | 69 |
Synta Pharmaceuticals Corp.
Synta Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Synta Pharmaceuticals Corp. discovers, develops and commercializes pharmaceutical products. It focuses on the research, development and commercialization of oncology medicines that provides treatment to cancer patients. The company is also developing a proprietary platform for delivery of anti-cancer drugs directly to tumor cells, known as Hsp90-inhibitor drug conjugates. Synta Pharmaceuticals was founded by Safi R. Bahcall and Lan-Bo Chen in March 2000 and is headquartered in Lexington, MA. | 2 anni |
| Roy E. Hahn | M | 72 |
Coopers & Lybrand LLP
| 16 anni |
| Donald William Kufe | M | 79 |
Synta Pharmaceuticals Corp.
Synta Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Synta Pharmaceuticals Corp. discovers, develops and commercializes pharmaceutical products. It focuses on the research, development and commercialization of oncology medicines that provides treatment to cancer patients. The company is also developing a proprietary platform for delivery of anti-cancer drugs directly to tumor cells, known as Hsp90-inhibitor drug conjugates. Synta Pharmaceuticals was founded by Safi R. Bahcall and Lan-Bo Chen in March 2000 and is headquartered in Lexington, MA. | 6 anni |
| Robert Kloppenburg | M | - |
Synta Pharmaceuticals Corp.
Synta Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Synta Pharmaceuticals Corp. discovers, develops and commercializes pharmaceutical products. It focuses on the research, development and commercialization of oncology medicines that provides treatment to cancer patients. The company is also developing a proprietary platform for delivery of anti-cancer drugs directly to tumor cells, known as Hsp90-inhibitor drug conjugates. Synta Pharmaceuticals was founded by Safi R. Bahcall and Lan-Bo Chen in March 2000 and is headquartered in Lexington, MA. | - |
| Paul Friedman | M | 81 |
Synta Pharmaceuticals Corp.
Synta Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Synta Pharmaceuticals Corp. discovers, develops and commercializes pharmaceutical products. It focuses on the research, development and commercialization of oncology medicines that provides treatment to cancer patients. The company is also developing a proprietary platform for delivery of anti-cancer drugs directly to tumor cells, known as Hsp90-inhibitor drug conjugates. Synta Pharmaceuticals was founded by Safi R. Bahcall and Lan-Bo Chen in March 2000 and is headquartered in Lexington, MA. | 2 anni |
| Robert Schweitzer | M | 78 |
Coopers & Lybrand LLP
| 2 anni |
| Vicki Sato | M | 75 | 13 anni | |
| Lisa M. Bruneau | F | - | 7 anni | |
| Hank Beinstein | M | 81 |
Coopers & Lybrand LLP
| 8 anni |
| William Reardon | M | 78 |
Synta Pharmaceuticals Corp.
Synta Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Synta Pharmaceuticals Corp. discovers, develops and commercializes pharmaceutical products. It focuses on the research, development and commercialization of oncology medicines that provides treatment to cancer patients. The company is also developing a proprietary platform for delivery of anti-cancer drugs directly to tumor cells, known as Hsp90-inhibitor drug conjugates. Synta Pharmaceuticals was founded by Safi R. Bahcall and Lan-Bo Chen in March 2000 and is headquartered in Lexington, MA. | 12 anni |
| Eric W. Jacobson | M | 66 |
Synta Pharmaceuticals Corp.
Synta Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Synta Pharmaceuticals Corp. discovers, develops and commercializes pharmaceutical products. It focuses on the research, development and commercialization of oncology medicines that provides treatment to cancer patients. The company is also developing a proprietary platform for delivery of anti-cancer drugs directly to tumor cells, known as Hsp90-inhibitor drug conjugates. Synta Pharmaceuticals was founded by Safi R. Bahcall and Lan-Bo Chen in March 2000 and is headquartered in Lexington, MA. | 4 anni |
| Dvorit Samid | M | - |
Synta Pharmaceuticals Corp.
Synta Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Synta Pharmaceuticals Corp. discovers, develops and commercializes pharmaceutical products. It focuses on the research, development and commercialization of oncology medicines that provides treatment to cancer patients. The company is also developing a proprietary platform for delivery of anti-cancer drugs directly to tumor cells, known as Hsp90-inhibitor drug conjugates. Synta Pharmaceuticals was founded by Safi R. Bahcall and Lan-Bo Chen in March 2000 and is headquartered in Lexington, MA. | - |
| Christine Redmond | F | - |
Synta Pharmaceuticals Corp.
Synta Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Synta Pharmaceuticals Corp. discovers, develops and commercializes pharmaceutical products. It focuses on the research, development and commercialization of oncology medicines that provides treatment to cancer patients. The company is also developing a proprietary platform for delivery of anti-cancer drugs directly to tumor cells, known as Hsp90-inhibitor drug conjugates. Synta Pharmaceuticals was founded by Safi R. Bahcall and Lan-Bo Chen in March 2000 and is headquartered in Lexington, MA. | - |
| Lan Bo Chen | M | 80 |
Synta Pharmaceuticals Corp.
Synta Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Synta Pharmaceuticals Corp. discovers, develops and commercializes pharmaceutical products. It focuses on the research, development and commercialization of oncology medicines that provides treatment to cancer patients. The company is also developing a proprietary platform for delivery of anti-cancer drugs directly to tumor cells, known as Hsp90-inhibitor drug conjugates. Synta Pharmaceuticals was founded by Safi R. Bahcall and Lan-Bo Chen in March 2000 and is headquartered in Lexington, MA. | 11 anni |
| Karuna Rubin | F | 47 | 6 anni | |
| Karim Meddahi | M | - |
Coopers & Lybrand LLP
| 4 anni |
| Douglas S. McCorkle | M | 67 |
Coopers & Lybrand LLP
| 6 anni |
| Craig W. Bottger | M | - |
Coopers & Lybrand LLP
| 12 anni |
| Bjorn Hanson | M | 72 |
Coopers & Lybrand LLP
| - |
| Frank Simpkins | M | 61 |
Coopers & Lybrand LLP
| - |
| Andrea Sprole | F | - |
Coopers & Lybrand LLP
| - |
| Gareth Powell | M | - |
Coopers & Lybrand LLP
| - |
| John Tobison | M | 68 |
Coopers & Lybrand LLP
| 10 anni |
| Craig L. McKnight | M | 72 |
Coopers & Lybrand LLP
| 10 anni |
| Stephen Quinn | M | - |
Coopers & Lybrand LLP
| 3 anni |
| Alex G. Stallings | M | 56 |
Coopers & Lybrand LLP
| 6 anni |
| Donald Alan Sherman | M | 73 |
Coopers & Lybrand LLP
| 8 anni |
| Hardie Brad Kimbrough | M | - |
Coopers & Lybrand LLP
| 7 anni |
| Cheryl A. Taylor | F | 56 |
Coopers & Lybrand LLP
| 5 anni |
| David Sung | M | 70 |
Coopers & Lybrand LLP
| 5 anni |
| Fredrick W. Weber | M | - |
Coopers & Lybrand LLP
| 12 anni |
| William Rutsey | M | 77 |
Coopers & Lybrand LLP
| 7 anni |
| David E. Doherty | M | - |
Coopers & Lybrand LLP
| 3 anni |
| John Gilliam | M | 69 |
Coopers & Lybrand LLP
| - |
| Thomas D. Fertitta | M | - |
Coopers & Lybrand LLP
| 11 anni |
| John Gregory Martinez | M | - |
Coopers & Lybrand LLP
| 8 anni |
| Markus Thomas Hilti | M | 73 |
Coopers & Lybrand LLP
| 3 anni |
| Rodney Whitley | M | - |
Coopers & Lybrand LLP
| 9 anni |
| Jon Miller | M | 67 |
Coopers & Lybrand LLP
| - |
| David MacMillan | M | - |
Coopers & Lybrand LLP
| 6 anni |
| David W. Chambers | M | 73 |
Coopers & Lybrand LLP
| 4 anni |
| Derek White | M | 62 |
Coopers & Lybrand LLP
| 6 anni |
| Michael P. Bauer | M | 59 |
Coopers & Lybrand LLP
| 5 anni |
| Steve G. Fracchia | M | - |
Coopers & Lybrand LLP
| 3 anni |
| Alex Hill | M | - |
Coopers & Lybrand LLP
| - |
| Mark A. Spears | M | 61 |
Coopers & Lybrand LLP
| 11 anni |
| Richard O. Lund | M | 74 |
Coopers & Lybrand LLP
| 9 anni |
| Ken Murley | M | - |
Coopers & Lybrand LLP
| - |
| Mark E. Bulmer | M | - |
Coopers & Lybrand LLP
| 2 anni |
| Thomas C. Gentry | M | - |
Coopers & Lybrand LLP
| 4 anni |
| Ralph G. D'Ambrosio | M | 56 |
Coopers & Lybrand LLP
| - |
| George Paz | M | 68 |
Coopers & Lybrand LLP
| 5 anni |
| Patrick B. Collins | M | 95 |
Coopers & Lybrand LLP
| 24 anni |
| Peter L. Eidelman | M | 57 |
Coopers & Lybrand LLP
| 5 anni |
| Robert Schechter | M | 76 |
Coopers & Lybrand LLP
| 14 anni |
| Eric Draut | M | 67 |
Coopers & Lybrand LLP
| 8 anni |
| Jeffrey Jones | M | 62 |
Coopers & Lybrand LLP
| 7 anni |
| Gregg R. Bodnar | M | 59 |
Coopers & Lybrand LLP
| 5 anni |
| Durwood C. Settles | M | - |
Coopers & Lybrand LLP
| 9 anni |
| Andrea Robertson | F | 66 |
Coopers & Lybrand LLP
| 3 anni |
| Fredricka Taubitz | F | 80 |
Coopers & Lybrand LLP
| - |
| Jeffrey Rudolph | M | 63 |
Coopers & Lybrand LLP
| 11 anni |
| Brian Goebel | M | 57 |
Coopers & Lybrand LLP
| 8 anni |
| Charles Wagner | M | 56 |
Coopers & Lybrand LLP
| 5 anni |
| Hans A. Haefeli | M | 65 |
Coopers & Lybrand LLP
| 4 anni |
| William J. Shea | M | 76 |
Coopers & Lybrand LLP
| 2 anni |
| Michael Howard | M | 60 |
Coopers & Lybrand LLP
| 11 anni |
| Michael K. Templin | M | - |
Coopers & Lybrand LLP
| - |
| Brian Wasserman | M | 58 |
Coopers & Lybrand LLP
| 5 anni |
| Keith Ray Godwin | M | 56 |
Coopers & Lybrand LLP
| 5 anni |
| Jonathan Michael | M | 70 |
Coopers & Lybrand LLP
| 5 anni |
| Timothy Philip | M | 60 |
Coopers & Lybrand LLP
| - |
| Laura Francis | F | 57 |
Coopers & Lybrand LLP
| 5 anni |
| Todd Fry | M | 58 |
Coopers & Lybrand LLP
| 6 anni |
| Monica M. Garver | F | - |
Coopers & Lybrand LLP
| - |
| Robert Young | M | 67 |
Coopers & Lybrand LLP
| 11 anni |
| Diane Irvine | M | 65 |
Coopers & Lybrand LLP
| 13 anni |
| Julian Dominic Schild | M | 64 |
Coopers & Lybrand LLP
| - |
| Roxanne Martino | F | 67 |
Coopers & Lybrand LLP
| 6 anni |
| Frank Hallam | M | 64 |
Coopers & Lybrand LLP
| 4 anni |
| Thomas Ryan | M | 58 |
Coopers & Lybrand LLP
| 8 anni |
| Jay S. Benet | M | 71 |
Coopers & Lybrand LLP
| 14 anni |
| Michael J. Brenner | M | - |
Coopers & Lybrand LLP
| 11 anni |
| Bill Hench | M | - |
Coopers & Lybrand LLP
| - |
| John Pierre DeVillars | M | 74 |
Coopers & Lybrand LLP
| 3 anni |
| Terri K. Maupin | F | 62 |
Coopers & Lybrand LLP
| 6 anni |
| Gregory A. Marsh | M | 63 |
Coopers & Lybrand LLP
| 8 anni |
| Sean Traynor | M | 55 |
Coopers & Lybrand LLP
| 3 anni |
| Timothy G. Rubritz | M | 70 |
Coopers & Lybrand LLP
| 9 anni |
| Samuel K. Ackerman | M | - |
OraVax, Inc.
 OraVax, Inc. BiotechnologyHealth Technology Part of Sanofi, OraVax, Inc. is a company that has a slick name that taps into the words 'oral' and 'vaccine' in a subtle way. The company is based in Cambridge, MA. The company is a possible oral health brand, medical licensing service, app, or chemicals company. OraVax was acquired by Acambis Plc, part of Sanofi from September 22, 2008 on May 11, 1999 for $17.79 million. | - |
| Timothy M. Mooney | M | 76 |
Coopers & Lybrand LLP
| 19 anni |
| Philip Joffe | M | 69 |
Coopers & Lybrand LLP
| 6 anni |
Statistiche
| Paese | Relazioni | % del totale |
|---|---|---|
| Italia | 79 | 79.00% |
| Stati Uniti | 21 | 21.00% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Keith S. Ehrlich
- Contatti personali
